Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours Β· Estimated delivery Aug 9 - Aug 14
This product is supplied strictly for laboratory research use only
A Phase I safety study and a Phase II ulcerative colitis trial of the BPC-157 formulation PL 14736 were conducted by the Croatian pharmaceutical company Pliva, but full peer-reviewed Phase II efficacy results have not been published
Unlike anti-inflammatory drugs that can impair healing by suppressing necessary processes, the combination modulates inflammation appropriately reducing the excess that causes tissue damage while preserving whats needed for debris clearance and the start of healing
skin vs recovery vs body composition) but the standard of care is the same
Healing tissues require a consistent blood supply for oxygen and nutrients, and multiple studies indicate that BPC-157 may augment the activity of vascular endothelial growth factor (VEGF), a crucial signal for angiogenesis
(2) K.Skrlec et al (2018) Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities Applied Microbiology and Biotechnology, Volume 102, pages 1010310117, (06 September 2018)
